Aspiriant LLC Has $868,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Aspiriant LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,668 shares of the medical research company’s stock after buying an additional 43 shares during the period. Aspiriant LLC’s holdings in Thermo Fisher Scientific were worth $868,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TMO. Intech Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 19.4% in the second quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company’s stock valued at $1,738,000 after purchasing an additional 510 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Thermo Fisher Scientific by 6.2% during the second quarter. Pacer Advisors Inc. now owns 28,900 shares of the medical research company’s stock worth $15,982,000 after purchasing an additional 1,685 shares during the period. Westwood Holdings Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 80.5% in the second quarter. Westwood Holdings Group Inc. now owns 2,226 shares of the medical research company’s stock valued at $1,231,000 after purchasing an additional 993 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 12.8% in the second quarter. ProShare Advisors LLC now owns 59,607 shares of the medical research company’s stock valued at $32,963,000 after purchasing an additional 6,783 shares in the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $66,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 0.4 %

Thermo Fisher Scientific stock opened at $559.72 on Tuesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm has a market capitalization of $214.09 billion, a PE ratio of 35.09, a P/E/G ratio of 3.71 and a beta of 0.76. The company’s 50-day moving average is $529.96 and its 200-day moving average is $568.56. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the prior year, the business earned $5.69 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific announced that its board has approved a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Royal Bank of Canada lowered their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 target price for the company. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.